Money to Bern

17 October 2016 By Jeffrey Goldfarb

The U.S. senator sent shares of leukemia drug maker Ariad tumbling after he knocked its price increases. Statements by UK Prime Minister Theresa May and other officials also have affected a range of valuations. Investors will need to adjust to this direct kind of political risk.

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)